Jiangsu Zhongbang Pharmaceutical Co., Ltd

Company Description

Wholly owned by the state-run large-scaled red sun group corporation, Jiangsu zhongbang pharmacy co. Ltd. Has a total investment of rmb200 million, and takes up a land of 200,000 square meters. It is a hi-tech enterprise mainly developing and producing l-ephedrine serial products, heart and brain blood vessel disease, infection, respiration system, metabolism and incretion, with the technology base of Nanjing red sun engineering technology center and Nanjing red sun biological pharmacy engineering technology center it constantly promotes the strength in the raw material synthesizing pyridine ramification, R&D of new medicine, and innovation of formulations. Meanwhile the company carries out end-reaching sales business of medicines with the support of the strong medicine operating network, sales foundation, and clinical teams of Jiangsu haibang pharmacy co. Ltd.

The company has completed the building of synthesizing workshops for raw material medicine, refine-dryness-package, and solid formulations, all meeting the gmp standard.. With a perfect and rigorous quality safeguard system, the company guarantees production quality and provides a Jiangsu Zhongbang Pharmaceutical Co., Ltdll-equipped off-sales service system.

With its competitive technology advantage, strong capital, excellent R&D, outstanding quality, first class production and technology, the company aims to become a renowned large-scale pharmacy company that has its self-owned intellectual property, a rational production structure, and strong core competitiveness, and a resources combination and transforming body with the integration of R&D, production, and sales of medicines.

The company is ready for close cooperation and joint development with friends in the business of raw material medicine synthesizing, new medicine development, and production sales.

Company Information

  • Business Type:Manufacturer
  • Year Established:1998
  • Number Of Employees:101 - 200 People
  • Total Revenue:Below US$1 Million
  • Trade Capacity:North America : 11.11% South America : 11.11%
  • Production Capacity:- -
  • R&D Capacity:No. of R&D Staff :11 - 20 People
  • Main Products:We Manufacture Bulk Drug And Intermediates., Pharmaceutical Chemicals
  • Main Markets:North America, South America, Western Europe, East
  • Location:Jiangsu, China (Mainland)

Product

  • Telmisartan
  • Lansoprazole
  • Pharmaceutical Chemicals
Countries   China   India   Indonesia   Malaysia   Pakistan   Turkey   United Kingdom   United States   All Countries